Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04326439 |
Title | AflacLL1901 (CHOA-AML) |
Recruitment | Terminated |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Emory University |
Indications | |
Therapies |
Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin |
Age Groups: | child | adult |
Covered Countries | USA |